Hepion Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 2 Study

(24/7 MARKET NEWS) – Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) announced, this morning, positive topline results, including improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF, from its recently completed Phase 2 ALTITUDE-NASH clinical trial.

Hepion Pharmaceuticals is trading at $13.05, up $4.14 (+48.46%), on 1.47M premarket shares traded.

Its 52-week range is $5.20 to $23.854. It’s blown through all of its recent resistance and, if its trading volume increases, it has a pathway to new 52-week highs.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist